Eli Lilly’s donanemab wins FDA approval for Alzheimer’s disease

Leqembi will now face a challenger as donanemab enters the market under the brand name Kisunla.

Jul 4, 2024 - 04:00

Eli Lilly’s donanemab wins FDA approval for Alzheimer’s disease

Leqembi will now face a challenger as donanemab enters the market under the brand name Kisunla.

Read the original article

Tags:

Previous Article

Left in limbo: When pharma halts rare disease research

Deal on Cancer ADC Gets Canceled by Eisai and Bristol Myers

What's Your Reaction?

0

Like

0

Dislike

0

Love

0

Funny

0

Angry

0

Sad

0

Wow

Related Posts

Having celiac disease and a thyroid condition sent her on a quest to become an empathetic doctor

Having celiac disease and a thyroid condition sent her ...

Aug 19, 2023

Magenta Therapeutics and Dianthus agree to merge operations

Magenta Therapeutics and Dianthus agree to merge operat...

May 4, 2023

AstraZeneca completes Fusion Pharmaceuticals acquisition

AstraZeneca completes Fusion Pharmaceuticals acquisition

Jun 6, 2024